Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Autologous GD2-CAR T Cells in Relapsed/Refractory Neuroblastoma
NCT06684639Phase 1Recruiting
- Sponsor
- General Hospital of Western Theater Command of PLA
- Start
- Dec 2024
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GD2.CAR-TVS-CTL in neuroblastoma, sponsored by General Hospital of Western Theater Command of PLA. Primary endpoints: Number of Adverse Events at 24 months and Overall Response Rate at 24 months. Started Dec 2024; status: recruiting.
02
Drugs
GD2.CAR-TVS-CTL
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06684639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684639.